Etiprednol dicloacetate

DB05442InvestigationalSmall molecule

Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease. Anti-asthmatic effects were associated with decreased cytokine production... Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture.

Primary indication: Investigated for use/treatment in asthma and crohn's disease.Curator reviewed
Formula / weight: C₂₄H₃₀Cl₂O₆ · 485.4 g/mol (avg)
Code names: BNP-166

Resolves to

Compound

UNII332VLD554FCAS199331-40-3ChEMBLCHEMBL2107614ChEBI135783PubChem9935073

Structure

InChIKeyQAIOVDNCIZSSSF-RFAJLIJZSA-NSMILES[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Targets

P04150NR3C1P01584IL1B

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etiprednol dicloacetate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account